These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27486973)

  • 1. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
    Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I
    Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
    Liu C; Armstrong C; Zhu Y; Lou W; Gao AC
    Oncotarget; 2016 May; 7(22):32210-20. PubMed ID: 27049719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
    Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.
    Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K
    Mol Oncol; 2024 Aug; 18(8):1980-2000. PubMed ID: 38600681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
    Richards J; Lim AC; Hay CW; Taylor AE; Wingate A; Nowakowska K; Pezaro C; Carreira S; Goodall J; Arlt W; McEwan IJ; de Bono JS; Attard G
    Cancer Res; 2012 May; 72(9):2176-82. PubMed ID: 22411952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
    Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
    Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M; Antonarakis ES; Luo J
    Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reciprocal regulation between RACGAP1 and AR contributes to endocrine therapy resistance in prostate cancer.
    Wang J; Liu H; Yu Z; Zhou Q; Sun F; Han J; Gao L; Dou B; Zhang H; Fu J; Jia W; Chen W; Hu J; Han B
    Cell Commun Signal; 2024 Jun; 22(1):339. PubMed ID: 38898473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
    Asangani IA; Wilder-Romans K; Dommeti VL; Krishnamurthy PM; Apel IJ; Escara-Wilke J; Plymate SR; Navone NM; Wang S; Feng FY; Chinnaiyan AM
    Mol Cancer Res; 2016 Apr; 14(4):324-31. PubMed ID: 26792867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
    Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer.
    Shiota M; Ushijima M; Tsukahara S; Nagakawa S; Okada T; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
    Free Radic Biol Med; 2024 Aug; 221():81-88. PubMed ID: 38762061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
    Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.